Societal cost savings through bevacizumab-based treatment in non-small cell lung cancer (NSCLC)

Stanisic, Sanja; Bischoff, Helge; Heigener, David F.; Vergnenègre, A.; Carpeño, Javier de Castro; Chouaïd, C.; Walzer, Stefan; Mueller, E; Schmidt, Elvira

doi:10.1016/s0169-5002(10)70135-5

Cited by 13 publications

(15 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Country cancer registries have been used to assess the overall morbidity from lung cancer 31,32. A study by Stanisic et al assessed the economic burden of metastatic NSCLC from a societal perspective,27 and found that the mean cost savings after one year were €21,667, €21,171, €17,578, and €12,401 in France, Germany, Italy, and Spain, respectively. The study results suggest that there are reduced productivity losses due to improved progression-free survival in patients treated with bevacizumab-based therapy compared with patients treated with chemotherapy alone.…”

Section: Discussionmentioning

confidence: 99%

“…A high level of health care resource utilization and a significant productivity loss were observed 26. Another study found that bevacizumab-based treatment can result in substantial cost savings in patients with advanced NSCLC who are progression-free 27. The aim of this study was to explore the incremental societal savings attributable to bevacizumab-based treatment compared with chemotherapy in France, Germany, Italy, and Spain.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Societal savings in patients with advanced non-squamous non-small-cell lung cancer receiving bevacizumab-based versus non-bevacizumab-based treatments in France, Germany, Italy, and Spain

Lister¹,

Stanisic²,

Kaier³

et al. 2012

CEOR

Self Cite

View full text Add to dashboard Cite

BackgroundThe purpose of this study was to investigate the savings accrued using bevacizumab-based treatment for non-small-cell lung cancer from the societal perspective, taking only public costs into account, in France, Germany, Italy, and Spain.MethodsSocietal costs were estimated by collecting and analyzing labor costs, carer costs, sickness benefits, disability benefits, and home care benefits. Cost inputs were derived from publicly available databases or from the published literature. Expert opinion was only used if no other source was available. Efficacy data from two randomized clinical trials were used. The time horizon in the health economic model was lifetime. Efficacy and costs were discounted by 3.5%. All main model parameters were tested in deterministic and probabilistic sensitivity analyses.ResultsMean incremental savings to society per patient ranged from €2277 in Italy to €4461 in Germany. The results were most sensitive to the change in proportion of patients working fulltime and the proportion of patients who were able to return to work.ConclusionThis analysis shows that bevacizumab-based treatment in non-small-cell lung cancer is associated with more savings to society compared to standard chemotherapy in terms of increased productivity and decreased social benefits paid to patients who are able to work in France, Germany, Italy, and Spain.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Societal savings in patients with advanced non-squamous non-small-cell lung cancer receiving bevacizumab-based versus non-bevacizumab-based treatments in France, Germany, Italy, and Spain

Lister¹,

Stanisic²,

Kaier³

et al. 2012

CEOR

Self Cite

View full text Add to dashboard Cite

show abstract

“…This regimen can largely prevent cancer recurrence or metastasis and improve overall outcome. Unfortunately, due to the indolent course of NSCLC, many patients present with advanced stage tumors at initial diagnosis [2]. Chemotherapy with cisplatin, paclitaxel, doxorubicin and gemcitabine agents are used for these poor surgical candidates, and often combined to improve efficacy and reduce toxicity [3456].…”

Section: Introductionmentioning

confidence: 99%

Metabolism and excretion of novel pulmonary-targeting docetaxel liposome in rabbits

Wang

Zhang

Wang

et al. 2017

Korean J Physiol Pharmacol

View full text Add to dashboard Cite

Our study aims to determine the metabolism and excretion of novel pulmonary-targeting docetaxel liposome (DTX-LP) using the in vitro and in vivo animal experimental models. The metabolism and excretion of DTX-LP and intravenous DTX (DTX-IN) in New Zealand rabbits were determined with ultraperformance liquid chromatography tandem mass spectrometry. We found DTX-LP and DTX-IN were similarly degraded in vitro by liver homogenates and microsomes, but not metabolized by lung homogenates. Ultra-performance liquid chromatography tandem mass spectrometry identified two shared DTX metabolites. The unconfirmed metabolite Mun differed structurally from all DTX metabolites identified to date. DTX-LP likewise had a similar in vivo metabolism to DTX-IN. Conversely, DTX-LP showed significantly diminished excretion in rabbit feces or urine, approximately halving the cumulative excretion rates compared to DTX-IN. Liposomal delivery of DTX did not alter the in vitro or in vivo drug metabolism. Delayed excretion of pulmonary-targeting DTX-LP may greatly enhance the therapeutic efficacy and reduce the systemic toxicity in the chemotherapy of non-small cell lung cancer. The identification of Mun may further suggest an alternative species-specific metabolic pathway.

show abstract

“…The same study detailed the cost of administering incredibly complex lung-cancer treatment, including the numerous subsequent algorithms for said treatment. It also evidenced that the costs of such treatment are often based on different forms of cost estimation, such as social cost and absenteeism [23].…”

Section: Introductionmentioning

confidence: 99%

Cost and reimbursement analysis of selected hospital diagnoses via activity-based costing

Popesko¹,

Papadaki²,

Новак³

2015

E+M

View full text Add to dashboard Cite

Societal cost savings through bevacizumab-based treatment in non-small cell lung cancer (NSCLC)

Cited by 13 publications

References 13 publications

Societal savings in patients with advanced non-squamous non-small-cell lung cancer receiving bevacizumab-based versus non-bevacizumab-based treatments in France, Germany, Italy, and Spain

Societal savings in patients with advanced non-squamous non-small-cell lung cancer receiving bevacizumab-based versus non-bevacizumab-based treatments in France, Germany, Italy, and Spain

Metabolism and excretion of novel pulmonary-targeting docetaxel liposome in rabbits

Cost and reimbursement analysis of selected hospital diagnoses via activity-based costing

Contact Info

Product

Resources

About